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Transgenic mouse models of HIV-associated nephropathy
(HIVAN) show that expression of HIV-1 genes in kidney cells
produces collapsing focal segmental glomerulosclerosis and
microcystic tubular disease typical of the human disease.
HIV-1 vpr plays an important role in the glomerulosclerosis
of HIVAN, especially when it is associated with nef expression
in podocytes. Further, Vpr is reported to exacerbate tubular
pathology. Here we determined effects of vpr expression on
renal tubular epithelial cell function by transducing them
with a pseudotyped lentivirus vector carrying HIV-1 vpr and
control genes. Vpr expression in the cultured cells impaired
cytokinesis causing cell enlargement and multinucleation.
This profound in vitro phenotype caused us to reexamine the
HIVAN mouse model and human HIVAN biopsies to see if
similar changes occur in vivo. Both showed abundant
hypertrophic tubule cells similar to the in vitro finding that
represents a previously unappreciated aspect of the human
disease. Additionally, multinucleated tubular cells were
identified in the murine HIVAN model and increased
chromosome number was detected in tubular cells of human
HIVAN biopsies. Our study provides evidence of a new clinical
phenotype in HIVAN that may result from the ability of Vpr to
impair cytokinesis.
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Human immunodeficiency virus (HIV)-associated nephropa-
thy (HIVAN) was first reported in 1984 when a small group of
Haitian and African-American HIV patients were found to
have decreased renal function independent of other risk
factors.1 Currently, HIVAN prevalence in the black HIV-
infected population is between 3.5 and 12%,2,3 affecting an
estimated 1–3 million people worldwide. HIVAN is associated
with direct HIV infection of the glomerular and tubular
compartments and subsequent viral genome transcription.4,5
The classical histopathologic features of HIVAN are collapsing
focal segmental glomerulosclerosis and focal microcystic (3
normal diameter) dilation of the tubular segments with
epithelial flattening.6–9 Apoptosis, hyperplasia, pseudocrescent
formation, and several other pathologic findings have also been
reported.9–12 Grossly, HIVAN kidneys are typically enlarged.
Transgenic models expressing either single HIV-1 genes or
deletion mutants of HIV-1 have been useful in mapping the
HIV-1 genes pathogenic for HIVAN. HIV-1 nef has been
associated with podocyte dedifferentiation and prolifera-
tion.13–15 HIV-1 vpr has been found to contribute to overall
HIVAN pathogenesis in both podocytes and tubule epithelial
cells.16 Mice expressing only vpr manifested some microcystic
tubule dilation, whereas those expressing HIV without vpr
did not show this phenotype. When HIVDvpr mice were
crossed with vpr-expressing mice, the offspring showed
widespread microcystic dilation typical of HIVAN. These
data suggest that the tubular cystic phenotype involves vpr
expression, but the exact mechanism of how Vpr contributes
to HIVAN pathogenesis remains unknown.
Although HIV-1 vpr function has not been investigated in
renal epithelial cells, it has been extensively studied in other
cell systems. In activated lymphocytes, and many cell lines,
Vpr induces G2 arrest followed by apoptosis. Expression of
vpr in other cell types, however, causes nuclear anomalies,
including hyperploidy, micronuclei formation, and the
evidence of impaired cytokinesis.17–21 Conversely, in macro-
phages, Vpr does not induce an abnormal nuclear phenotype
or apoptosis, but may instead be important for HIV
replication by facilitating nuclear import of the HIV pre-
integration complex.22,23
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The precise mechanism(s) by which Vpr alters cell
function is incompletely understood, but recently multiple
studies have identified DDB1–Cullin 4A Associated Factor 1
(DCAF1) as an important Vpr binding partner.24–28 DCAF1
binds an E3 ubiquitin ligase complex likely functioning as a
substrate specificity module. Vpr binding to DCAF1 is
proposed to dysregulate and usurp the E3 complex. This
binding appears to be the critical upstream event mediating
Vpr-induced G2 arrest. Downstream, several events have been
reported, notably the presence of stalled DNA replication
forks in primary CD4þ lymphocytes.29 This DNA stress then
triggers the ataxia telangiectasia mutated related (ATR)
response pathway that causes G2 arrest and also initiates
apoptosis.30 The mechanism by which the interaction
between Vpr and the E3 ubiquitin ligase complex leads to
this phenotype in lymphocytes is a topic of investigation.
Despite several studies implicating a role for HIV-1 vpr in
HIVAN, the mechanism underlying its role in the tubular
disease is unknown. Given that Vpr is linked to a number of
pathologic phenotypes that are cell type specific, we aimed to
determine the effect of Vpr on the renal tubular epithelium.
In this study, we examined the effect of HIV-1 Vpr on human
tubular epithelial cells in vitro and correlated these findings
in vivo to reveal new aspects of HIVAN pathology.
RESULTS
Efficient transduction of HK2 cells using a pseudotyped
lentivirus vector
Determining the effect of HIV-1 vpr expression in human
proximal tubule epithelial cell (PTECs) required an efficient
transduction system. Therefore, a pseudotyped lentivirus
vector with a broadly tropic VSV.G envelope was used to
deliver the expression cassettes to PTEC (Figure 1a). All
transfer plasmids contained either a green fluorescent protein
(GFP) or RFP reporter gene to monitor infection efficiency
by both microscopy and fluorescence-activated cell sorting
(Figure 1b). The pHR-GFP vector transduced 95.5% of cells,
and this level of efficiency is representative for all plasmids.
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Figure 1 | Expression of HIV-1 vpr in PTECs causes cell enlargement and inhibits cell growth. (a) Schematic representation of the HIV-1
provirus deletion construct and pHR constructs that include green or red fluorescent protein reporters (GFP or RFP). LTR – HIV-1 Long
terminal repeat promoter. Psi, packaging sequence; RRE, Rev response element; CMV, cytomegalovirus immediate early promoter; IRES,
internal ribosome entry site. (b) VSV.G pseudotyped lentivirus generated with pHR-GFP efficiently transduced HK2 cells. Flow cytometry was
used to determine the fraction of GFP-expressing cells at 48 h after transduction. (c) Normal sized (left panel) and enlarged HK2 cells
(center and right panels) at 48 h after transduction with pseudotyped lentivirus containing pHR-GFP or pHR-Vpr vectors as indicated.
(d) Growth restriction of HK2 cells after transduction with pseudotyped lentivirus containing pHR-Vpr or pNL4-3Dgag/pol (HIV-1) vectors.
Untransduced HK2 cells or HK2 cells transduced with pseudotyped lentivirus containing pHR-GFP, pHR-Vpu, or pHR-Vif proliferated equally.
Fold growth was obtained by counting cells manually in the same random field over 3 days. The mean and s.d. of fold growths for four
random fields are plotted. *Indicates t-test significance of Po0.0001 compared both with the uninfected control.
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HIV-1 Vpr causes cell enlargement and restricts proliferation
in the HK2 proximal tubule cell line
When HK2 cells expressed vpr, the cells became visibly
enlarged compared with the pHR-GFP control (Figure 1c).
Some HIV-1Dgag/pol expressing HK2 cells also increased in
size, although the majority became smaller undergoing
apoptosis as has been reported.31 Cells infected with pHR-
Vpu and pHR-Vif expression vectors were also not enlarged
(data not shown).
pHR-Vpr-transduced PTECs also had altered cell growth.
Renal proximal tubule cell proliferation rates were deter-
mined over 3 days in cells transduced with lentiviral vectors.
HIV-1 vpr expression was associated with a loss of cell
proliferation, whereas pHR-GFP-transduced cells proliferated
at a rate comparable to uninfected cells (Figure 1d). HIV-
1Dgag/pol also blocked HK2 cell proliferation over this time
period. HIV-1 vpu and vif did not have any effect on
proliferation and served as additional controls given their size
and viral origin. Notably, HIV-1 vif has been reported to be
cytostatic and/or cytotoxic in other cell systems demonstrat-
ing the importance of cell type.32
To rule out a trans effect mediated by Vpr protein expres-
sion in the lentivirus producer 293T cells, viral supernatants
were collected and filtered using a 100 kDa protein filter that
would remove virus but not soluble proteins. When the
filtered supernatant was applied to HK2 cells, no GFP-
positive cells were observed and no growth restriction or cell
size increase was seen (data not shown). This result indicated
that lentivirus transduction and subsequent intracellular vpr
expression, and not any other soluble factor, is responsible for
growth restriction. In conclusion, these studies demonstrate
that the expression of HIV-1 vpr prevents proliferation and
causes the enlargement of PTECs in vitro.
HIV-1 vpr causes cell cycle dysregulation in HK2 cells
HIV-1 Vpr has been reported to induce G2 arrest in other cell
types. Therefore, we determined if cell cycle arrest was
associated with the restriction of HK2 cell proliferation. Cells
were transduced as described and analyzed for cell cycle
changes 48 h later. A majority of HIV-1 vpr-transduced cells
were in the G2 or hyperploid state, whereas GFP transduction
had no effect on the cell cycle. Furthermore, full-length
HIV-1 also induced hyperploidy and G2 accumulation but
Vif alone or Tat alone did not (Figure 2a). The greater
fraction of cells in G2 seen with full-length HIV-1 transduc-
tion may result from Vpr synergism with other viral proteins.
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Figure 2 | HIV-1 Vpr causes cell cycle dysregulation in PTECs. (a) Cell cycle analysis of HK2 cells at 48 h after transduction with
pseudotyped lentivirus containing pNL4-3Dgag/pol, pHR-Vpr, pHR-Tat, or pHR-Vif as indicated. The gates for G1, S, G2, and 4G2 are shown
for each panel. The percentage of cells within those gates is indicated in the upper right corner of each panel. (b) Propidium iodide-stained
nuclei of HK2 cells 72 h after transduction with pseudotyped lentivirus containing pHR-Vpr (upper panel) or pHR-GFP (lower panel) vectors.
Examples of multinucleated cells (arrows) and cells with single enlarged nuclei (arrowheads) are shown. The original magnification was
 400. (c) Cell cycle analysis of HK2 cells 24 h after treatment with dihydrocytochalasin B or DMSO or transduced with pseudotyped
lentivirus containing the pHR-Vpr vector as indicated.
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Examining the nuclei of vpr-transduced HK2 cells revealed
some mononuclear cells with large nuclei and possibly
increased DNA content (Figure 2b). Also prevalent were
multinucleated cells, suggesting that the cause of the
increased 4N and 8N populations was nuclear division in
the absence of cytokinesis rather than checkpoint-mediated
G2 arrest. HK2 cell fusion was not visualized, although we
cannot rule out that it contributed to HK2 multinucleation.
Lastly, HK2 cells were treated with the microtubule
depolymerizing agent dihydrocytochalasin B to indepen-
dently impair cytokinesis. The morphology and cell cycle
profiles of dihydrocytochalasin B-treated and vpr-expressing
cells were similar and both showed increased G2 and 8N
populations (Figure 2c). This result indicates that the cell
cycle dysregulation caused by Vpr in PTECs is consistent with
impaired cytokinesis.
This phenotype is similar to that described in studies by
Shimura et al.19–21 in a stable vpr inducible cell line.
HIV-1 vpr expression induces apoptosis in HK2 cells
Because full-length HIV-1 induces apoptosis in PTEC and
tubule cell apoptosis is seen in HIVAN, we determined if Vpr
could cause PTEC apoptosis.31,33 By two independent
methods, sub-G1 peak analysis and Annexin V staining, a
modest but significant increase in apoptosis was seen in cells
expressing HIV-1 vpr compared with control (Figure 3a and b).
A time course following vpr transduction revealed that
apoptosis was highest after 4 days and followed the onset of
the cell cycle changes (Figure 3b). Although Vpr contri-
butes to HIV-1-induced apoptosis in PTECs, it is probably
not the sole cause. Apoptosis of renal tubule cells is a feature
of the pathology seen in both human HIVAN biopsies and
the murine model of HIVAN.34,35
Vpr-R80A and Vpr-Q65R do not impair PTEC cytokinesis
Single amino acid Vpr variants were used to determine the
molecular domain of Vpr involved in impaired cytokinesis in
PTEC. Other Vpr mutagenesis studies have implicated
domains in the basic C terminus as particularly important
for the induction of G2 arrest in lymphocytes. However, no
Vpr mutagenesis studies had been performed to investigate
the domains involved in the inhibition of cytokinesis.
Therefore, it was unclear if the same domain of Vpr would
mediate both phenotypes. We examined the variants Vpr-
R80A, Vpr-Q65R, Vpr-R77Q, and Vpr-I74A for their ability
to induce cell cycle changes. Consistent with their activities in
checkpoint-mediated G2 arrest, neither Vpr-R80A nor Vpr-
Q65R inhibited cytokinesis in PTECs, whereas Vpr-R77Q
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Figure 3 | HIV-1 Vpr causes apoptosis in PTECs. (a) Quantification of apoptotic HK2 cells at 96 h after transduction with pseudotyped lentivirus
containing pHR-Vpr or pHR-GFP vectors. Representative (left and center panels) and averaged (right panel) annexin V staining and PI
counter-staining are shown. *Indicates t-test significance of Po0.0005. (b) Time course of cell cycle and apoptosis changes in HK2 cells transduced
with pseudotyped lentivirus containing pHR-Vpr or pHR-GFP. The sub-G1 peak was used as a second assay of apoptosis in this experiment.
Cell cycle analysis including this sub-G1 peak is shown at 4 days after infection for pHR-GFP and pHR-Vpr-infected HK2 cells (offset right).
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and Vpr-I74A had a phenotype similar to wild-type Vpr
(Figure 4a). Vpr-R80A and Vpr-Q65R expressions were
indistinguishable from the control vector with regard to
proliferation and cell morphology (data not shown).
Because the same amino acid substitutions abrogate the
Vpr-induced phenotype in both T cells and proximal tubule
cells, the same upstream protein-binding event may be
important in both settings.
Vpr inhibition of PTEC cytokinesis is not abrogated by the
ATR/ataxia telangiectasia mutated inhibitor caffeine
In lymphocytes, ATR is believed to be the critical mediator of
the DNA damage response, which results after vpr expression
and leads to G2 arrest.36 Therefore, caffeine, an inhibitor of
ATR, is commonly used as an in vitro inhibitor of Vpr
activity. PTECs already expressing vpr were treated with
caffeine in an attempt to restore cytokinesis. PTECs were first
infected with pHR-Vpr or control pHR-GFP lentivirus vector
and at 48 h treated with 1–3 mM caffeine. No significant
change in the cell cycle profile was observed in cells treated
with caffeine compared with those untreated (Figure 4b).
These results suggest that the Vpr impairment of cytokinesis
is independent of the ATR pathway. Although this conclusion
differs from Vpr studies in lymphocytes, it is consistent with
other results where a similar phenotype was also resistant to
caffeine.17 A possible explanation for why Vpr shows cell type
specificity is the expression of ATR itself. Although lympho-
cytes, HeLa cells, and many tissue types express ATR, cDNA
from human kidney shows almost no ATR expression at all.37
Increased HK2 cell protein correlates with the increase in
cellular DNA
HIV-1 vpr expression in PTECs is associated with cell
enlargement and multinucleation with impaired cytokinesis.
To determine whether the cell enlargement observed was
proportional to an increase in genomic DNA, HK2 cells were
infected with either pHR-Vpr or control virus and at 48 h,
DNA and protein content were measured and normalized to
cell number (Table 1). As expected, we found vpr-expressing
cells had, on average, a 55.8% increase in DNA content and a
65.2% increase in protein content. However, these values
resulted in no statistically significant difference in the DNA/
protein ratio (the molecular measure of hypertrophy) of vpr-
transduced cells compared with control cells.38 Therefore, the
PTEC enlargement most likely results from a physiologic size
increase prior to cytokinesis.
HIV-1 induces hypertrophy and multinucleation in vivo
in the murine model of HIVAN
HIV-1 vpr expression in PTECs in vitro caused apoptosis and
impaired cytokinesis, leading to enlarged cells with multiple
nuclei. Apoptosis is described in the HIVAN murine model
and human biopsies. However, neither tubular cell hyper-
trophy nor multinucleation has been noted. Therefore, we
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Figure 4 | HIV-1 Vpr variants R80A and Q65R are inactive for cell cycle dysregulation in PTECs. (a) Cell cycle analysis of HK2 cells at
48 h after transduction with pseudotyped lentivirus containing pHR-GFP, pHR-Vpr, pHR-Vpr-I74A, pHR-Vpr-R77Q, pHR-Vpr-Q65R, or
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time indicated (shown as hours after the pseudotyped lentivirus transduction with pHR-Vpr). The normalized G1 fraction was defined as
(G1% at t0, t48, or t96 h)/(G1% at t0) and plotted as indicated.
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examined the Tg26 transgenic mouse, a model of HIVAN
that expresses all of the HIV genes except gag and pol and
shows classic HIVAN pathology (Figure 5a). The kidney
sections from nephrotic (3þ proteinuria) mice were
inspected for enlarged and multinucleated tubule cells.
Surprisingly, frequent examples of enlarged cells and multi-
nucleated cells were seen (Figure 5b and c). Tubular cell
hypertrophy was evident when comparing control with
murine HIVAN at the same magnification. For each
comparison, the HIVAN kidneys always had larger tubules
appearing as if they were examined at a higher magnification
(Figure 5b). These results resemble the phenotype seen when
vpr is expressed in PTECs in vitro resulting in enlarged and
multinucleated cells (Figure 2b).
Tubular cell hypertrophy and increased chromosome number
is observed in HIVAN
The examination of human HIVAN biopsy samples also
revealed widespread hypertrophy similar to the murine
HIVAN model (Figure 6). HIVAN biopsies had larger tubules
compared with control human kidney biopsies with in-
dividual tubule cell hypertrophy also being apparent. In these
HIVAN biopsies, multinucleation could not be conclusively
demonstrated. However, many tubular cell nuclei were
enlarged mimicking vpr expression in vitro. To determine if
these nuclei had increased DNA content, we applied
fluorescence in situ hybridization to the centromeric regions
of chromosomes 8, X, and Y. Nuclei exceeding a diploid
signal were indicative of increased DNA. The technique
required 2mm sections, much thinner than the diameter of a
typical cell nucleus. Therefore, the signal number under-
estimated the actual chromosome number in the large
majority of nuclei. This effect can be appreciated in a field
view of the control kidney sample (Figure 7a upper panel).
The arrow depicts a diploid tubular cell but neighboring cells
show fewer hybridization signals. In contrast to the control,
the HIVAN sample showed many tubular cell nuclei with an
increased number of centromere hybridization signals (Figure
7a lower panel—arrowed, Figure 7b, and c). These results
demonstrate a previously unrecognized aspect of HIVAN
pathology that correlates with Vpr activity in vitro.
DISCUSSION
The microcystic distortion of the tubulointerstitium is one of
the most striking features of HIVAN. We now know that
HIV-1 infects tubular cells in patients with HIVAN. In situ
hybridization and laser capture microscopy combined with
PCR have shown that HIV-1 mRNA is expressed in tubular
cells and replicates within the renal compartment in HIVAN
×400
Murine HIVANControl
Control Murine HIVAN Murine HIVAN
Murine HIVANControl
×200 ×200
×400
Murine HIVAN
Figure 5 | Tubular cell hypertrophy and multinucleation in the murine HIVAN model. (a) Control murine kidney compared with murine
HIVAN kidney at an original magnification of  200. A dilated tubule (arrowhead) and sclerotic glomeruli (arrow) are shown. (b) Tubular cell
hypertrophy in murine HIVAN. Control and murine HIVAN sections were compared at an original magnification of  400. General
hypertrophy can be appreciated and examples of individual cell hypertrophy and nucleus enlargement are shown (arrows). (c) Examples of
control murine kidney tubules and multinucleated tubule cells in murine HIVAN. The original magnification was  600. All sections are PAS
stains.
Table 1 | The protein content and DNA content of HK2 cells at
48 h after transduction with lentivirus containing pHR-Vpr or
pHR-GFP as indicated
pHR-VPR/pHR-GFP
Protein/DNA DNA/cell Protein/cell
Average 1.06 1.56 1.65
s.d. (s) 0.11 0.16 0.03
The ratios shown indicate the mean and s.d. of a single experiment performed in
triplicate. This experiment was representative of three experiments.
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patients.4,5 HIV expression within transgenic mouse kidney
produces the characteristic features of the disease that are
identical to those observed in humans.39 As reported
previously, tubular cell apoptosis is common and epithelial
dedifferentiation is widespread as evidenced by changes in
expression levels and patterns of characteristic cellular markers.
The viral genes responsible for the tubular disease have
not been defined nor has the mechanism been well
established. Previous work has provided some insights;
however, Dickie et al.40 reported increased tubular pathology
in transgenic mice expressing HIV-1 vpr, suggesting that Vpr
has an important role in this aspect of HIVAN pathogenesis.
HIV-1 vpr expression has already been shown to induce G2
cell cycle arrest and apoptosis of CD4þ T cells. Thus, we
hypothesized that Vpr might induce similar pathology in the
renal tubule epithelium (RTE) of HIVAN patients and
transgenic mice, although, ultimately, we found a different
mechanism was responsible.
To explore the possible role of Vpr in producing disease in
tubular cells in HIVAN, we used an in vitro model of the
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Red-X 
Figure 7 | Increased chromosome number in tubule cells in human HIVAN biopsies. (a) Renal FISH staining on a female human control
(upper panel) and male human HIVAN biopsy (lower panel). L, tubular lumen; arrows, cell of normal ploidy (control) or increased ploidy
(HIVAN). Centromeric enumeration probes (CEP) are Aqua, chromosome 8; red, chromosome X; and green, chromosome Y. The original
magnification of control and HIVAN sections was  1000. (b) Selected examples of tubular cells with increased copy number for X and/or
Y chromosomes in human HIVAN biopsies. (c) Selected examples of tubular cells with increased copy number of chromosome 8 in
human HIVAN biopsies.
HIVAN PASControl PAS
×400 ×400 ×400 ×400
HIVAN PASHIVAN PAS
Figure 6 | Tubule cell hypertrophy in human HIVAN biopsies. Compared with normal adult control kidney, the HIVAN kidneys display
increased tubular diameter of noncystic tubules and diffuse hypertrophy of individual tubular epithelial cells. The original magnification
of control and HIVAN sections was  400. All sections are PAS stains.
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human proximal tubule cell and efficiently expressed HIV-1
vpr using a lentiviral vector. This approach allowed a detailed
phenotypic analysis of the vpr-transduced cells and provided
insight into Vpr’s pathologic mechanisms.
In this study, we found that Vpr induced significant
apoptosis in tubular cells in vitro. More prominently,
however, the vpr expressing tubular cells became enlarged
with enlarged or multiple nuclei. As this phenotype was not
previously described in vivo, we examined kidney sections
from the murine HIVAN model and human HIVAN biopsies.
Surprisingly, RTE hypertrophy was striking in both mouse
and human. Both RTE cell size and nuclei were significantly
larger in both transgenic and HIVAN kidneys when
compared with controls. We also found multinucleated
RTE cells in transgenic mice. Although terms such as
‘reactive’ epithelial cells have been used before to describe
some of these findings, the extent of cellular changes
observed in both mouse and human is striking. In addition,
the tubule cell hypertrophy may contribute to the gross
pathologic kidney enlargement in HIVAN. On the basis of
these findings in vitro and in vivo, we conclude that Vpr
contributes to HIVAN tubular pathology by interfering with
and disrupting tubule epithelial cell division. However, the
examination of vpr transgenic murine models for hypertro-
phy and multinucleation will determine whether HIV-1 vpr
expression is sufficient to cause these changes in vivo or it
works in conjunction with other HIV proteins.
Normally, the renal tubule epithelium is in a quiescent,
non-proliferative state (G0). In response to acute injury,
however, RTE cells have the capacity to proliferate.38
Previously we reported that a large fraction of tubule cells
in the kidneys of HIV transgenic mice are positive for the
proliferation marker Ki-67.35 This finding indicates that
many tubule epithelial cells have re-entered the cell cycle. The
impetus for cells exiting G0 is not entirely clear but could be
in response to the concurrent apoptosis induced by HIV,
epithelial injury, or a viral gene product such as Nef, which is
known to induce proliferation.15 Whatever the cause, Vpr
appears to interfere with tubule cell division leading to cell
enlargement and multinucleation.
The mechanism of Vpr-induced enlargement and multi-
nucleation was investigated in vitro and appears to result
from a specific defect in cell cytokinesis. HK2 cells expressing
vpr continued to cycle through S phase, often multiple times,
without cytokinesis occurring. This phenotype is distinct
from Vpr-induced G2 arrest in lymphocytes where the cell
cycle stops prior to mitosis through a classical checkpoint
pathway. Differentiated proximal tubular epithelial cells
display a Vpr phenotype similar to what has been described
in various cell lines, primary HUVECs, and yeast.17,18,20,41
Vpr functions as an adaptor protein between an unknown
target protein and DCAF1, a substrate specificity module in
certain Cullin 4-based E3 ubiquitin ligase complexes.
Proteasomal degradation of this putative target protein is
proposed to trigger G2 arrest, apoptosis, and potentially
other phenotypes induced by HIV-1 vpr expression. The
critical binding site of Vpr has been mapped by mutagenesis
of the key amino acids between positions 65 and 80. The
mutation of the Q65 residue prevents DCAF1 binding and
impairs the ability of Vpr to induce G2 arrest.26,38 Other
mutations that retain binding to DCAF1 can also inhibit the
ability of Vpr to induce G2 arrest, possibly because the ability
to bind to the unknown target protein is lost. Examples of
such mutations include R73A, G75A, C76A, R80A, and
R90A. In our study we examined four mutants, and the
results were consistent with previous studies. Mutants I74A
and R77Q acted as wild type, whereas both R80A and Q65R
were completely inactive.
Although there is a strong correlation between the in vitro
Vpr phenotype in PTEC and pathology seen in the murine
HIVAN model and HIVAN biopsies, hypertrophy, irregular
cell division, and apoptosis are not the only tubular patho-
logies associated with HIVAN. Microcystic dilation remains
an unexplained hallmark of HIVAN. We have shown
previously that the cells lining the microcysts of transgenic
mice are flattened with less brush border and no longer
support transcription of HIV-1.35 One possibility is that
microcyst formation is an end-stage result that arises after an
initial hypertrophic expansion, and hypertrophied HIV-1-
expressing cells have died or transformed.
In conclusion, we report that Vpr impairs cytokinesis in
proximal tubular epithelial cells leading to cell enlargement
and often multinucleation. The examination of kidney
sections from human and mouse showed extensive tubular
hypertrophy, multinucleation, and evidence of increased
chromosome number. These in vivo results reveal new aspects
of HIVAN pathology. Given Vpr’s central role in HIVAN
pathogenesis, we anticipate it may provide a good molecular
target for future therapeutic intervention.
MATERIALS AND METHODS
Cell culture system
The HK2 line of human proximal tubule cells was obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and
cultured in Defined Keratinocyte Serum-Free Media (Gibco,
Carlsbad CA, USA, 17005-042) with 5 ng/ml of recombinant
epidermal growth factor and 0.05 mg/ml of bovine pituitary extract
at 37.0 1C, 5% CO2 to preserve phenotype. Ryan et al.
42 character-
ized this line as phenotypically similar to freshly isolated PTECs
including Naþ -dependent sugar transport. 293T Cells were used to
produce pseudotyped virus and cultured in Dulbecco’s modified
Eagle’s medium with fetal bovine serum (10%), penicillin (10,000 U/
ml), and streptomycin (10 mg/ml).
Pseudotyped lentivirus vector infection
A pseudotyped lentivirus vector was used to efficiently transduce the
desired genes into the HK2 cell line. This virus was produced by co-
transfection (Invitrogen Lipofectamine 2000, Invitrogen (Carlsbad,
CA, USA)) of 293T cells with three separate plasmids: pVSV.G
expressing the VSV envelope, the packaging plasmid pHIVgag/pol
expression gag and pol in trans, and the specific viral or pHR
plasmid expressing the package RNA as previously described.15
Forty-eight hours after plasmid transfection, the supernatant was
collected and filtered using a 0.45 mm filter (Millipore, Billerica, MA,
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USA). Virus was titered by infection of 293T cells, and an
multiplicity of infection of 3 was used to infect PTECs to achieve
maximum infection.
Proliferation assay
The cell proliferation assay was performed by flow cytometry
(FACSCalibur, BD Biosciences, San Jose, CA, USA). Forward scatter
(FSCþ ) side scatter (SSCþ ) events were counted for a set interval
at flow speeds low, medium, and high. All values are at sub-
confluence. Error bars reflect the intra-assay variability and are
representative of a minimum of two independent experiments.
Cell cycle assay and analysis
Cell cycle analysis was performed by flow cytometry (FACSCalibur
and FacScan, BD Biosciences, San Jose, CA, USA). Cells were fixed
and permeabilized by the addition of 20 1C ethanol to a final
concentration of 50%. The fixed cells were treated with 100 mg/ml of
propidium iodide and 0.5mg/ml of RNAse A for 3 h prior to
cytometry. FloJo (version 6.4.7) was used for all analysis.
Microscopy
Cells were fixed in cold 100% ethanol and stained with propidium
iodide (3 mM) for 10 min at room temperature and examined.
Representative fields were photographed in fluorescent and mono-
chrome light and merged for publication.
Apoptosis assays
Quantification of the sub-G1 peak in cell cycle analysis was
measured as a fraction of a FSCþ SSCþ -gated population.
Annexin V staining was performed using Annexin V-APC antibody
(Molecular Probes, Carlsbad CA, USA, A35110) at 5 ml per 1 106
cells. Propidium iodide co-staining was performed at final
concentration of 1.5 mg/ml.
Drug treatments
Caffeine (Fisher Scientific, Hampton, NH, USA) was dissolved in
water applied to PTECs at a final concentration of 1–3 mM.
Dihydrocytochalasin B (Fisher Scientific) in dimethyl sulfoxide
solution was applied to PTECs at a final concentration of 10 mM.
DNA and protein quantification
HK2 cells were infected as described and resuspended 48 h later.
DNA and protein were harvested from equal volumes of
resuspended cells in triplicate. DNA and protein concentrations
were measured by spectrophotometry using the NanoDrop ND-
1000 Thermo Scientific, Wilmington, DE, USA. Values were
normalized to cell number as measured by flow cytometry. The
data shown are representative of two independent experiments.
Histology
HIV transgenic (Tg26 murine line) FVB/N mice with 3-plus
proteinuria were killed and examined. Comparisons were made to
wild-type FVB/N mice. Human HIVAN biopsies were compared
with normal control biopsies. Representative areas were chosen for
publication.
Fluorescence in situ hybridization
Human HIVAN biopsies were fixed in paraffin and cut to 2 mm
sections on positively charged silanized glass slides. Deparaffiniza-
tion and pretreatment of the slides were performed according to the
Vysis Paraffin Pretreatment Kit III protocol (Vysis/Abbott Mole-
cular, Abbott Park, IL, USA). Denaturation of the target DNA on
slides and probes was performed simultaneously at 73 1C for 6 min
on a Thermobrite System (Vysis/Abbott Molecular). Hybridization
was carried out in a humidified chamber at 37 1C overnight using
chromosome enumeration probe 8 (CEP-8, Abbott Molecular,
32-131008) and/or CEP-X/CEP-Y (Abbott Molecular, 30-161050).
40-6-Diamidino-2-phenylindole (Vysis/Abbott Molecular) was used
as a counterstain. The slides were analyzed and imaged with the
Cytovysion 3.92 program (Applied Imaging/Genetix, New Milton,
UK) and Axioplan II microscope (Zeiss, Oberkochen, Germany).
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